Sign inJoin waitlistJoin the waitlist

Sangeetha Venugopal

Assistant Professor of Clinical Medicine, Hematology · University of Miami/Jackson Health System

Credentials: · · · ·

History

University of Miami/Jackson Health System
Present

Hematology
2017–2018
Internal Medicine
Montefiore Einstein
2014–2017
Madurai Medical College
1999–2003

Research

FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm
Review · Blood Cancer Journal · 2021 · Co-first of 3 authors · 132 citations
Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy
Blood Cancer Journal · 2022 · First of 19 authors · 85 citations
Admission D-dimer levels, D-dimer trends, and outcomes in COVID-19
Thrombosis Research · 2020 · 78 citations

Naval Daver
16 papers
Tapan Kadia
13 papers
Courtney DiNardo
12 papers
Hagop Kantarjian
12 papers
John Mascarenhas
12 papers
Mikkael Sekeres
11 papers
Nicholas Short
11 papers
GB
Gautam Borthakur
10 papers
Guillermo Garcia-Manero
10 papers
KS
Koji Sasaki
9 papers
Marina Konopleva
9 papers
Sanam Loghavi
8 papers

Clinical trials

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Site PI · Recruiting · Phase 2
M.D. Anderson Cancer Center
2024–2029
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2024–2027
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Site PI · Recruiting · Phase 1, Phase 2
Disc Medicine, Inc
2022–2027